Ocugen

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More


Abzena in Bristol

Abzena Amplifies Bioconjugate Development and Manufacturing with $5 Million Bristol Site Expansion

BRISTOL, PA — Abzena has unveiled a $5 million investment to enhance its Bristol, Pennsylvania facility, specializing in bioconjugate development and cGMP (current Good Manufacturing Practice) manufacturing. This substantial financial …

Abzena Amplifies Bioconjugate Development and Manufacturing with $5 Million Bristol Site Expansion Read More
Helius Medical Technologies

Helius Medical Technologies: Strides Towards Reimbursement for Innovative PoNS Therapy Amidst Financial Challenges

NEWTOWN, PA — In a market landscape dominated by titans in the biotech and healthcare technology sectors, Helius Medical Technologies, Inc. (Nasdaq: HSDT) found themselves in a David versus Goliath …

Helius Medical Technologies: Strides Towards Reimbursement for Innovative PoNS Therapy Amidst Financial Challenges Read More